Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Nutraceuticals and Dietary Supplements for Older Adults with Long COVID-19

Matteo Tosato, MD, PhD, Francesca Ciciarello, MD, Maria Beatrice Zazzara, MD, Cristina Pais, MD, Giulia Savera, MSC, Anna Picca, PhD, Vincenzo Galluzzo, MD, Hélio José Coelho-Júnior, PhD, Riccardo Calvani, PhD,* Emanuele Marzetti, MD, PhD, Francesco Landi, MD, PhD, on behalf of Gemelli Against COVID-19 Post-Acute Care Team

INTRODUCTION

SARS-CoV-2 infection affects multiple organs owing to the ubiquitous distribution of its target receptor ACE-2.\(^1\) Increasing interest has been paid to the postacute phase of COVID-19. The time to recover from an acute COVID-19 episode ranges from 2 to 6 weeks depending on disease severity.\(^2\) However, a substantial share of people reports clinical sequelae weeks or months after symptom onset. This condition, known as postacute COVID-19 syndrome, postacute sequelae of COVID-19, or long COVID syndrome, encompasses long-lasting signs and symptoms, such as cough, dyspnea, fatigue, and muscle weakness.\(^3\)

KEYWORDS

- Geriatrics
- Gerontology
- Frailty
- Sarcopenia
- Fatigue
- Nutrition
- Bioactive foods
- Therapy

KEY POINTS

- Long-term persistence of COVID-19–related symptoms after SARS-CoV-2 infection impacts quality of life.
- Several mechanisms may be involved in the persistence of COVID-19 symptoms, including chronic inflammation, immunometabolic processes, endothelial dysfunction, and gut dysbiosis.
- Bioactive foods, supplements, and nutraceuticals may be used for the management of long-term COVID-19 clinical sequelae.

INTRODUCTION

SARS-CoV-2 infection affects multiple organs owing to the ubiquitous distribution of its target receptor ACE-2.\(^1\) Increasing interest has been paid to the postacute phase of COVID-19. The time to recover from an acute COVID-19 episode ranges from 2 to 6 weeks depending on disease severity.\(^2\) However, a substantial share of people reports clinical sequelae weeks or months after symptom onset. This condition, known as postacute COVID-19 syndrome, postacute sequelae of COVID-19, or long COVID syndrome, encompasses long-lasting signs and symptoms, such as cough, dyspnea,
fatigue, difficulties with memory and concentration ("brain fog"), sleep disorders, gastrointestinal complaints, and musculoskeletal problems.\textsuperscript{3,4}

A recent systematic review showed that more than half of COVID-19 survivors (mostly middle-aged men hospitalized during the acute phase) had at least one long-lasting symptom at 6 months.\textsuperscript{5} Results from a digital questionnaire in a cohort of middle-aged nonhospitalized patients with COVID-19 from Denmark showed that persistent symptoms lasting for more than 4 weeks were experienced by 36\% of participants who had been symptomatic during the acute phase.\textsuperscript{6} Recently, our group showed that persisting symptoms were common in older adults who had been hospitalized for COVID-19, with approximately 50\% of the sample presenting with 3 or more symptoms after 3 months of hospital discharge.\textsuperscript{7} Symptom persistence was more frequent in those who experienced fatigue during acute COVID-19.

The mechanisms of chronic COVID-19 manifestations have not been yet unveiled. Several hypotheses are currently being tested.\textsuperscript{4,8} These include viral persistence associated with chronic inflammation, autoimmune processes, alterations in immunometabolic pathways, dysbiosis, endothelial damage, and unresolved organ damage.\textsuperscript{3,4,8} It is noteworthy that some of the immunologic and systemic features of long COVID resemble signs of accelerated or premature aging, and may aggravate pre-existing age-associated degenerative conditions, such as sarcopenia and cognitive decline.\textsuperscript{9–11}

Specific treatments for long COVID are currently lacking. Patient management mostly relies on symptomatic treatments and recommendations to conduct an active and healthy lifestyle. A plethora of dietary supplements and natural bioactive substances have been tested for their potential to contrast long COVID.\textsuperscript{12,13} In this review, the possible actions of nutraceuticals and dietary supplements on mechanisms associated with long COVID are described. A brief overview of ongoing studies investigating the effects of specific nutraceuticals in patients with long COVID attending the outpatient service at the Fondazione Policlinico A. Gemelli IRCCS (Rome, Italy)\textsuperscript{14} is presented.

**DISCUSSION**

**Amino Acids**

Amino acids play a crucial role in cell metabolism and modulate several biological processes (eg, inflammation, glucose homeostasis, redox balance) that may be involved in post-COVID clinical sequelae.\textsuperscript{4,8,15} Amino acids support the increased metabolic demands of activated immune cells by contributing critical intermediates to biosynthetic and energy-producing pathways, such as glycolysis, tricarboxylic acid (TCA) cycle, and oxidative phosphorylation pathways.\textsuperscript{15}

Glutamine replenishes TCA cycle intermediates that have been consumed in biosynthetic processes in T cells, macrophages, and plasma cells through anaplerosis.\textsuperscript{16–18} In immune cells, glutamine is also used for glutathione and in hexosamine biosynthetic pathways and supplies amino groups for other amino acids via transamination.\textsuperscript{19}

The branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are essential amino acids with well-established effects on protein synthesis and glucose homeostasis. BCAAs mainly act through the stimulation of cellular anabolic signaling pathways (eg, phosphoinositide 3-kinase–protein kinase B, mammalian target of rapamycin [mTOR]).\textsuperscript{20} BCAAs may exert direct and indirect effects on immune function.\textsuperscript{15} In vitro models have shown that BCAAs are essential for proliferating lymphocytes to synthesize proteins and nucleotides in response to stimulation.\textsuperscript{21} BCAAs can be
incorporated into and oxidized by immune cells. The amount of BCAAs incorporated into proteins is higher in lymphocytes, followed by eosinophils and neutrophils.\textsuperscript{21} In immune cells, BCAAs are also sources of the coenzyme A (CoA) derivatives acetyl-CoA and succinyl-CoA, which enter the TCA cycle and support mitochondrial bioenergetics.\textsuperscript{15} BCAAs may also improve gut mucosal surface defense by stimulating soluble immunoglobulin A secretion.\textsuperscript{22}

Arginine is a semiessential amino acid involved in multiple biological processes. Its main activities on the immune system derive from its conversion to nitric oxide (NO) by NO synthase (NOS) and its metabolism through arginase, that competes with NOS for arginine availability in most immune cells.\textsuperscript{23} NO is known to have direct and indirect antiviral activity through the generation of immunomodulatory oxidized phospholipids.\textsuperscript{24–26} NO also exerts potent anti-inflammatory effects via inhibition of leukocyte recruitment.\textsuperscript{27,28} Several studies in animal models have shown that the mechanisms of NO action on leukocyte function involve the activation of guanylyl cyclase, followed by the generation of cyclic GMP that suppresses the expression of P-selectin, a crucial mediator in leukocyte adhesion.\textsuperscript{29} Reduced arginine bioavailability may impair T-cell response and function.\textsuperscript{30} In patients with COVID-19, a decrease in plasma arginine levels with concomitant increase in arginase activity was associated with impaired T-cell proliferative capacity, which can be restored in vitro by arginine supplementation.\textsuperscript{31} Arginine, through its action on NO synthesis, may also modulate endothelial and respiratory functions and exert antithrombotic and cytoprotective activities.\textsuperscript{32} Preliminary data suggest that oral arginine supplementation added to standard therapy reduced the need of respiratory support and the duration of in-hospital stay in patients with severe COVID-19.\textsuperscript{33} Because of its modulating activities on inflammation and endothelial function, arginine has also been indicated as a plausible agent to contrast COVID-19 sequelae.

Collectively, available evidence suggests that amino acids are crucial to modulate immune response and several other mechanisms involved in both acute and chronic COVID-19. In older adults, the physiologic changes associated with the aging process (eg, increased splanchnic extraction, anabolic resistance, chronic inflammation) may further increase the need of adequate amino acid supplies.\textsuperscript{34} Protein/amino acid malnutrition in older adults is associated with immune dysfunction and sarcopenia, the latter being aggravated by reduced mobility and inflammatory processes induced by COVID-19.\textsuperscript{35}

Given these premises, it is reasonable to focus on the achievement of an adequate amino acid intake in COVID-19 survivors, also through oral supplementation. In particular, amino acid intake should be monitored in older people who are at greater risk of malnutrition as a specific consequence of SARS-CoV-2 infection.

\textit{Hydroxy-Beta-Methylbutyrate}

\textit{Beta-hydroxy-beta-methyl butyrate (HMB) is the active metabolite of leucine.}\textsuperscript{36} HMB, through the stimulation of mTOR-dependent pathways, modulates several physiologic processes, including protein metabolism, insulin activity, skeletal muscle hypertrophy, cell apoptosis, and muscle stem cell proliferation and differentiation.\textsuperscript{37}

Oral supplementation of HMB (3 g/d) mitigates the decline in muscle mass and preserves muscle function in older adults and frail people, especially during hospital stay and recovery.\textsuperscript{38} Interestingly, HMB may modulate the immune and inflammatory response, especially under stressful conditions.\textsuperscript{39} HMB supplementation was found to have short-term anti-inflammatory and anticatabolic effects and to improve pulmonary function in patients with chronic obstructive pulmonary disease in an intensive care unit setting.\textsuperscript{40}
Possible effects of HMB on brain have also been explored, starting from the evidence that HMB crosses the blood-brain barrier in rats. HMB was found to promote neurite outgrowth in vitro, and long-term HMB supplementation in rats attenuated age-related dendritic shrinkage of pyramidal neurons in the medial prefrontal cortex, thus suggesting possible beneficial effects on cognition.

Based on its well-established effects on muscle mass preservation and its potential biological activities on physiologic systems perturbed by COVID-19, HMB may represent a useful support for older patients suffering from long-term COVID-19 sequelae.

**Tricarboxylic Acid Cycle Intermediates**

Malic acid, citric acid, and succinic acid are TCA cycle intermediates with a well-established role in mitochondrial energy metabolism. Once considered byproducts of cellular metabolism to be used for the biosynthesis of macromolecules (eg, lipids, nucleotides, proteins), TCA cycle intermediates are now recognized as important mitochondrial signaling molecules regulating multiple cellular functions. Indeed, TCA cycle metabolites may also modulate chromatin remodeling, DNA methylation, posttranslational protein modifications, platelet activity, and immunity.

Supplementation with TCA cycle intermediates may help preserve mitochondrial biogenesis and function and fulfill the increased metabolic demands of older people recovering from COVID-19. In this context, TCA cycle metabolites may support the beneficial effects of amino acid supplementation in the prevention of mitochondrial dysfunction, oxidative damage, and muscle loss. Novel formulas combining mixtures of amino acids plus TCA intermediates, such as citric, succinic, and malic acid, and B group vitamins, were tested for their effects on mitochondrial bioenergetics and antioxidant response both in vitro and in animal models of aging. In murine neural stem cells and human-induced pluripotent stem cells, mitochondrial function, oxidant scavenging mechanisms, and neuronal stem cells differentiation were boosted via activation of the mechanistic target of rapamycin complex 1 and nuclear factor erythroid 2 like 2 (Nrf2)-mediated gene expression. In a mouse model of accelerated muscular and cognitive aging, the combination of amino acids plus TCA cycle metabolites and cofactors preserved mitochondrial efficiency, muscle mass, and physical and cognitive abilities by acting on proliferator-activated receptor γ coactivator 1α and NRF2 in skeletal muscle and hippocampus.

Further investigation is warranted to evaluate the potential effects of TCA cycle metabolites (alone or combined with other nutrients) to contrast long-term consequences of COVID-19.

**Micronutrients**

Nutritional surveys indicate that vitamin and mineral deficiencies are highly prevalent in older adults. Micronutrient deficiencies are associated with increased risk of non-communicable diseases, such as fatigue, cardiometabolic disease, musculoskeletal disorders, and cognitive impairment. Micronutrients, including selenium, iron, zinc, and magnesium, are also critical for the proper functioning of the immune system.

**Selenium**

Selenium is an essential trace element and is mainly present in the form of selenoproteins. Selenium is involved in several physiologic processes, including neurologic, endocrinologic, cardiovascular, and immune functions. Several studies have investigated the role of selenium in modulating the immune response, and for this reason, a putative role for selenium has been evoked in the
context of COVID-19. Evidence in human, animal, and cellular models suggests that selenium plays an important role in response to viral infections, including respiratory viruses, while its deficiency seems to increase host susceptibility to infections. Selenium supplementation stimulates innate immune system and increases CD4+ T cells and natural killer cell response. Selenium also modulates the secretion of proinflammatory interleukins by inhibiting nuclear factor κB (NF-κB). Selenium deficiency has been correlated to greater secretion of interleukin-6 (IL-6) in older adults, whereas higher levels of selenium are associated with reduced C-reactive protein (CRP) circulating levels. Low plasma concentration of selenium was also correlated with increased tissue damage and organ failure, prothrombotic activity, and overall mortality in patients in intensive care, which could explain a correlation with severity of symptoms in patients with COVID-19 and possible COVID-19 sequelae in long haulers. Several studies have reported that circulating selenium concentrations were lower in patients with COVID-19 as compared with healthy controls and associated with COVID-19 severity and mortality. Low selenium levels may increase individual susceptibility to SARS-CoV-2 infection, influence the severity of the disease, and be related to postacute sequelae and long-lasting symptoms.

Iron

Iron is essential for all living organisms, being a crucial component of hundreds of proteins involved in fundamental biological processes, including oxygen transport, energy production, and nucleic acid synthesis. During viral infections, the rapid viral proliferation determines a competition for iron between the invading pathogen and the host. Moreover, iron homeostasis influences both the innate and the adaptive host immune response. In fact, hypoferremia is linked to altered B- and T-lymphocyte proliferation and function and is associated with higher levels of proinflammatory cytokines and reactive oxygen species. Low-iron levels have been associated with the severity of respiratory insufficiency, acute multiorgan failure, and mortality in patients with COVID-19. Iron status parameters, such as ferritin, transferrin, and hepcidin, which respectively serve to store, transport, and absorb iron in the human body, may be considered risk factors and clinical biomarkers for COVID-19 prognosis. In particular, meta-analyses have correlated high-ferritin levels with COVID-19 severity and mortality. Ferritin stimulates the expression of proinflammatory cytokines, such as IL-1β, IL-6, IL-12, and tumor necrosis factor-α (TNF-α), and a gradual reduction of its circulating levels has been demonstrated in patients with COVID-19 after infusion of monoclonal antibodies targeting IL-6 receptor. Preliminary data from a prospective observational cohort study in patients with mild to critical COVID-19 show that alterations in iron homeostasis may persist for at least 2 months after acute infection and are associated with nonresolving lung disorders and impaired physical performance. Iron deficiency was associated with elevated levels of inflammation markers, such as IL-6 and CRP. Finally, low-iron levels could theoretically impair the efficacy of COVID-19 vaccination, underlining the importance of monitoring iron levels, especially in older adults with long COVID.

Based on the available evidence, iron supplementation, especially in older adults with low iron and hemoglobin levels, could be particularly useful for reducing the level of inflammation, mitigating persistent symptoms (such as fatigue and dyspnea), and improving immune response to vaccination.
Zinc

Zinc is the second most abundant trace metal in the human body after iron and is essential for the maintenance of immune health, cell homeostasis, and reproduction. Zinc deficiency is quite common in the general population and is also associated with immune dysfunction, affecting both the innate and the adaptive immune systems. Inadequate zinc intake has been associated with increased risk of upper- and lower-respiratory tract infections, especially in older adults, whereas supplementation with zinc gluconate seems to reduce duration and severity of common cold symptoms.

Zinc may inhibit coronavirus RNA polymerase activity in vitro and viral replication in cultured cells. Zinc has also an immunomodulatory, antioxidant, and anti-inflammatory role that could influence the trajectory of SARS-CoV-2 infection, and its supplementation could ameliorate lung function, enhance mucociliary clearance, and reduce ventilator-induced lung injury in critical patients with COVID-19. Lower serum zinc levels were found in patients with severe COVID-19 with acute respiratory distress syndrome and associated with a higher rate of complications and in-hospital length of stay. Zinc deficiency could also be connected to the onset and persistence of symptoms such as anosmia and dysgeusia, which can last for a variable amount of time after resolution of acute infection.

Zinc supplementation was tested for its potential role in contrasting the consequences of SARS-CoV-2 infection. However, available data on the efficacy of zinc supplementation for the management of patients with COVID-19 are scarce and contradictory. A prospective randomized clinical trial, COVID A to Z study, evaluated the efficacy of a treatment with zinc gluconate, ascorbic acid, or their combination in shortening the duration of COVID-19 symptoms. The study failed to demonstrate a significant improvement in symptoms, and the study was stopped for futility.

Further studies are needed to evaluate the effects of zinc or mixtures of micronutrients, including zinc in both acute COVID-19 and in long COVID-19 syndrome.

Magnesium

Magnesium is essential for several physiologic functions and biochemical reactions and may exert important anti-inflammatory and antioxidant functions. Although severe magnesium deficiency with clinical symptoms is quite rare, hypomagnesemia is frequent in patients in the intensive care unit, regardless of the cause of admission, and is associated with increased mortality, higher need for ventilator support and incidence of sepsis, and longer hospital stays. Although there are no significant data on magnesium homeostasis in patients with COVID-19, it has been suggested that magnesium deficiency could modulate the progress and severity of SARS-CoV-2 infection. Magnesium supplementation protects organs and tissues from damage through multiple mechanisms and could potentially influence the natural history of COVID-19.

It is well known that magnesium exerts anticholinergic, antihistaminic, and anti-inflammatory activities, reduces the risk of airway hyperreactivity and wheezing, and promotes bronchodilation by inhibiting bronchial smooth muscle contraction via blockage of calcium channels. A systematic review demonstrated that a single infusion of 1.2 or 2 g of magnesium sulfate in adults with exacerbations of asthma was associated with a reduction in hospitalization rate and improved lung function in patients who did not respond to standard treatment (ie, oxygen, nebulized short-acting β2-agonist, and intravenous corticosteroids). In addition, magnesium reduces
the secretion of transforming growth factor β1, thereby preventing lung fibrosis, a rare but fearsome consequence of COVID-19.

Magnesium plays a role in modulating the innate and adaptive immune system. Subclinical magnesium deficiency is correlated with low-grade chronic inflammation, which can be crucial for the prognosis of COVID-19 and the persistence of COVID-19 symptoms. It has been demonstrated that magnesium sulfate supplementation downregulates inflammatory response and oxidative stress by inhibiting chemokine and cytokines, such as IL-1, IL-6, IL-8, TNF-α, and CRP, which are often significantly elevated in severe COVID-19 cases. Magnesium may also modulate the adaptive immune system, influencing the proliferation and the activation of CD4+ and CD8+ T lymphocytes. Furthermore, magnesium exerts an important role in maintaining endothelial function and vascular integrity. In response to an acute inflammation stimulus, such as SARS-CoV-2 infection, the endothelium increases the secretion of prothrombotic factors. Accumulating evidence suggests that the endothelium might be directly affected in patients with COVID-19. Magnesium supplementation, especially in older adults, could help prevent the risk of thromboembolism in COVID-19 and long-term consequences in COVID-19 survivors. In critically ill patients with COVID-19, magnesium sulfate supplementation can represent a supportive treatment with promising beneficial effects. A retrospective observational study demonstrated that in hospitalized patients with COVID-19 aged 50 years and older, a combination of oral vitamin D3, magnesium, and vitamin B12 supplementation for up to 14 days significantly reduced the need of oxygen therapy compared with controls.

Despite the lack of clinical trials and well-powered studies in patients with COVID-19, magnesium supplementation seems to find a potential application in controlling respiratory symptoms, but also in modulating inflammation, cardiovascular and neurologic disorders, and electrolyte abnormalities. The monitoring of magnesium status should be encouraged, as it may influence immune homeostasis and help decrease morbidity and mortality in patients with COVID-19.

Bromelain

Bromelain is a proteolytic enzyme derived from the fruit and stem of pineapple. Bromelain is commonly used as an anti-inflammatory agent, although its potential biological activity spans from respiratory, digestive, immune, and circulatory systems to anticancer and antimicrobial therapy.

Bromelain regulates inflammatory processes through the modulation of NF-κB and cyclooxygenase 2 pathways that regulate the synthesis of inflammatory cytokines and prostaglandin E2 and thromboxane A2, respectively. Moreover, bromelain has fibrinolytic and antithrombotic properties and may also exert analgesic effects by regulating the synthesis of pain mediators, such as bradykinin. The decrease in bradykinin levels induced by bromelain may also indirectly act on inflammatory response through the regulation of vascular permeability and reduction in edema. Bromelain showed immunomodulatory effects both in vitro and in vivo. Bromelain may simultaneously enhance and inhibit T-cell responses by acting on accessory cells and directly on T cells. Moreover, bromelain enhanced T-cell–dependent, antigen-specific, B-cell antibody responses in vivo.

In vitro studies suggest that bromelain may also inhibit SARS-CoV-2 infection by targeting ACE-2, transmembrane serine protease 2, and SARS-CoV-2 S-protein. Considering its multiple potential activities on mechanisms involved in acute and chronic COVID-19 phases, bromelain could represent a candidate therapeutic agent for the management of COVID-19. In this context, bromelain may also increase the absorption of curcumin and other bioactive compounds with possible anti-COVID-19
activities after oral administration. Currently, data about the properties of bromelain on persistent symptoms related to long COVID-19 are lacking, but it can be hypothesized that its biological activities might help in the process of recovery from chronic fatigue, joint pain, and myalgia.

**Trozererutin**

Trozererutin is a flavonoid derived from rutin that can be found in tea, coffee, cereals, fruits, and vegetables. Trozererutin exerts multiple biological functions, including antioxidant, anti-inflammatory, nephroprotective, antithrombotic, antidiabetic, and neuroprotective effects. Following ingestion, flavonoids are partially digested by microbiome, which facilitates the absorption by small or large bowel.

Trozererutin exerts its antioxidant functions through direct free radical scavenging activity and by enhancing the activity of glutathione and antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase. Through its antioxidant activities, trozererutin might preserve epithelial cells, fibroblasts, and lymphocytes from oxidative stress-induced apoptosis.

Trozererutin was found to protect against gentamycin-induced acute kidney injury in rats through the downregulation of inflammatory cytokines (IL-10, TNF-α, and IL-6), the reduction of apoptotic cell death, and the induction of renal tissue regenerative capacity, by acting on p38 mitogen-activated protein kinase signaling. Trozererutin protects the hippocampus against amyloid-beta induced oxidative stress and apoptosis by reducing the acetylcholinesterase activity and oxidative stress. In a rat model of traumatic brain injury, trozererutin exerted multiple protective effects through the regulation of endothelial NOS activity. Moreover, trozererutin demonstrated anxiolytic- and antidepressant-like activities in rodents.

In rat models of type 1 and type 2 diabetes, trozererutin preserved male fertility and protected against diabetic cardiomyopathy through the reduction of reactive oxygen species and its activity of NF-κB, serine/threonine kinase 1, and insulin receptor substrate 1. Data on the activity of trozererutin in COVID-19 are currently lacking. However, its antioxidant and anti-inflammatory properties might be helpful for both the acute and the chronic consequences of SARS-CoV-2 infection.

**Lactoferrin**

Lactoferrin is an iron-binding glycoprotein, which acts as a host defense molecule against microbes. Lactoferrin is mainly secreted from exocrine glands and is present in granules in neutrophils following infections. Lactoferrin prevents microbial and viral adhesion to human cells through its iron-chelating ability, which reduces availability of iron used for microbial growth, aggregation, and biofilm formation. The activity of lactoferrin is mostly bacteriostatic, but a lethal effect has been demonstrated. One of its derivates, lactoferricin, tends to inactivate the lipid A from lipopolysaccharide of gram-negative bacteria. Lactoferrin may also have a bactericidal effect on gram-positive bacteria. Lactoferrin exerts its antiviral activity through different mechanisms at the mucosal level, including binding to heparan sulfate glycosaminoglycans, viral particles, and viral receptors, thus limiting viral entry.

In vitro, bovine lactoferrin blocks human cell apoptosis induced by influenza A virus. In vitro and in vivo studies showed that lactoferrin may also inhibit cytomegalovirus and herpes simplex virus infection. The antiviral activity of lactoferrin has been demonstrated against a multitude of viruses, including respiratory syncytial virus, poliovirus, hepatitis B virus, hepatitis C virus, alphaviruses, hantavirus, human papillomavirus, adenovirus, and enterovirus. Given its immunomodulatory and antiviral
properties, the use of lactoferrin was also proposed to contrast SARS-CoV-2 infection. In vitro and in silico assays showed that lactoferrin may have an antiviral activity against SARS-CoV-2 through direct attachment to both SARS-CoV-2 spike S glycoprotein and cell surface components. Lactoferrin may also modulate the inflammatory cascade through the reduction of IL-6, TNF-α, and ferritin levels. A preliminary study testing the antiviral effect of oral and intranasal liposomal bovine lactoferrin in asymptomatic and patients with mild to moderate COVID-19 showed that lactoferrin treatment induced fast symptom resolution compared with standard care. Treatment with lactoferrin also elicited a significant decrease in serum ferritin, IL-6, and D-dimer.

Based on available evidence, lactoferrin may represent a promising molecule to be used in both patients with acute COVID-19 or patients with postacute COVID-19 syndrome. Further investigations are needed to corroborate the positive preliminary findings obtained in patients with COVID-19, and to determine whether lactoferrin supplementation alone or with other bioactive compounds may result in additive beneficial effects against acute and postacute COVID-19.

**Probiotics**

The gastrointestinal system may be affected during acute and postacute COVID-19. Gastrointestinal symptoms, such as diarrhea, nausea, vomiting, and loss of appetite, are commonly experienced by people with COVID-19. SARS-CoV-2 RNA may be detected in stools even after viral clearance in the respiratory tract. Moreover, alterations in gut microbiota were associated with COVID-19 severity, possibly as a consequence of a "leaky gut" phenomenon and the release of microbial products and toxins into systemic circulation. Long-term antibiotic therapies, hospitalization, stress, comorbidities, and the direct action of SARS-CoV-2 on ACE2 receptor at the gastrointestinal level are associated with gut dysbiosis. Perturbations in gut microbiota may persist months after acute COVID-19 and may be associated with long-term complications.

Probiotics are “live microbes that, when administered in adequate amounts, confer health benefits on their hosts.” Probiotics (mainly Bifidobacteria and Lactobacilli) may exert relevant immunomodulatory functions on the gut-lung axis. Probiotics increase host mucosal defense through the stimulation of immunoglobulin A secretion, induce polarization of the immune response toward Th1, modulate cytokine production, and produce metabolites, such as short chain fatty acids, that contribute to set the tone of the immune system. Probiotics may have also anti-inflammatory, antioxidant, and antiviral properties. Interestingly, an in silico molecular docking approach suggested that metabolites from Lactobacillus plantarum may have potential antiviral activity against SARS-CoV-2 by targeting helicase nsp13. Probiotics may also have synergistic antiviral activities when combined with compounds with antimicrobial properties. For instance, Lacticaseibacillus paracasei DG strain enhances the lactoferrin anti–SARS-CoV-2 response in Caco-2 cells.

Numerous studies are currently testing the use of different mixtures of probiotics as adjunctive treatment for the management of both acute and postacute COVID-19. Preliminary evidence suggests that probiotics administration may reduce secondary infections in people with severe COVID-19. The consumption of a specific bacterial formulation containing strains of Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus paracasei, L plantarum, Lactobacillus brevis, and Bifidobacterium lactis was associated with remission of gastrointestinal symptoms and reduced risk of respiratory failure in hospitalized patients with COVID-19. In COVID-19 outpatients, the administration of a mixture of
Lactiplantibacillus plantarum and Pediococcus acidilactici strains improved viral clearance and reduced both respiratory and gastrointestinal symptoms compared with placebo.\textsuperscript{147}

Further studies are needed to assess the effects of specific probiotic formulations and/or the combination of probiotics with other bioactive compounds on long-term COVID-19 sequelae.

The use of probiotics may be particularly recommended in older patients with COVID-19, in whom age-related factors, including frailty, multimorbidity, and malnutrition, may aggravate gut dysbiosis.

**Vitamin D**

Vitamin D plays a crucial role in the regulation of calcium and bone metabolism.\textsuperscript{148} Accumulating evidence from preclinical and observational studies suggests that vitamin D could be involved in many extraskeletal pathways, including immune and muscle function, reproduction, and energy metabolism.\textsuperscript{146} Vitamin D may modulate different aspects of the innate and adaptive immune response.\textsuperscript{149} Both vitamin D receptor and enzymes involved in vitamin D metabolism are expressed by several immune cell types, including lymphocytes, monocytes, macrophages, and dendritic cells.\textsuperscript{149}

Vitamin D may support innate immunity by stimulating the synthesis of several antimicrobial peptides, including cathelicidins and defensins.\textsuperscript{150} Vitamin D may also regulate the activity of antigen-presenting cells, T- and B-cell differentiation, and the balance between proinflammatory and anti-inflammatory cytokines.\textsuperscript{151} Low vitamin D levels were associated with increased risk of numerous immune-related conditions, including type 1 diabetes,\textsuperscript{152} multiple sclerosis,\textsuperscript{153} and rheumatoid arthritis.\textsuperscript{154} Furthermore, people with vitamin D deficiency tend to be more prone to develop acute respiratory infections.\textsuperscript{155}

Vitamin D deficiency has been associated with increased risk of SARS-CoV-2 infection and worse clinical outcomes, including more severe lung impairment, need for respiratory support and intensive care, and mortality.\textsuperscript{156,157} Hence, vitamin D supplementation has been tested as a candidate adjunctive treatment for COVID-19. In asymptomatic or mildly symptomatic individuals with SARS-CoV-2 and vitamin D deficiency, a 7-day administration of high-dose vitamin D (60,000 IU of cholecalciferol per day) accelerated viral clearance compared with placebo.\textsuperscript{158} Vitamin D supplementation taken before or during COVID-19 was associated with better 3-month survival in older adults hospitalized for COVID-19 compared with nonsupplemented peers.\textsuperscript{159} However, a recent living systematic review found insufficient evidence to determine the benefits of vitamin D supplementation as a treatment of COVID-19, owing to the heterogeneity of studies, including different supplementation strategies, formulations, vitamin D status of participants, and reported outcomes.\textsuperscript{160}

As for postacute COVID-19, data on the association between vitamin D levels and the persistence of symptoms are scarce. In a small group of COVID-19 survivors from Dublin, persistent fatigue and reduced exercise tolerance were not associated with vitamin D levels.\textsuperscript{161}

Because of the multiple effects of vitamin D on biological pathways associated with long COVID and its relevance for the overall health status, vitamin D supplementation should be considered to avoid the detrimental consequences of vitamin deficiency. This holds true in particular for vulnerable people, such as older COVID-19 survivors, in whom vitamin D may also contrast geriatric conditions, such as frailty and sarcopenia, that are associated with negative health outcomes and may further reduce the quality of life.\textsuperscript{162}
Pollen-Based Herbal Extracts

Pollen, the male gametophyte of the flower, has long been used for therapeutic purposes by various ancient civilizations.\textsuperscript{163} Pollen contains a mixture of amino acids, carbohydrates, minerals, and bioactive substances that vary depending on the plant source and geographic origin, climatic conditions, soil type, and the activity of bees.\textsuperscript{164} Purified cytoplasm of pollen (PCP) is a nonhormonal herbal remedy used to manage vasomotor symptoms and sleep and mood disorders in menopausal women.\textsuperscript{165} Even if the mechanisms of action of PCP are not fully understood, this compound seems to act as a selective serotonin reuptake inhibitor (SSRI)-like agent to increase serotonin availability in hypothalamic serotonergic neurons. This explains, at least partly, its efficacy in controlling thermoregulation, and sleep and mood disorders in menopausal woman, without the adverse effects of currently prescribed SSRIs.\textsuperscript{166} Another putative mechanism action of PCP could be based on the precursors of serotonin. Indeed, tryptophan and methyl serotonins have been identified in low concentrations in PCP extracts, even if their contribution to intraneuronal serotonin synthesis could be negligible.\textsuperscript{166} Studies conducted in women with symptomatic menopause demonstrated that PCP supplementation improved sleep quality and quality of life and reduced hot flushes, fatigue, and muscle and joint pain.\textsuperscript{165,167} The most common symptoms complained of by COVID-19 long haulers are fatigue, muscle weakness, and sleep difficulties, with a higher risk of developing anxiety or depression. Given the accumulating evidence on the effects of PCP in contrasting these symptoms in menopausal women, it could be speculated that PCP may be used as a remedy to mitigate persisting symptoms in long COVID patients.

Beetroot Juice

Beetroot juice, which is obtained from the red beetroot (\textit{Beta vulgaris}), has spurred much attention owing to its potential beneficial effects on cardiovascular health, metabolic homeostasis, inflammation, and pulmonary function.\textsuperscript{168–170} The multiple health benefits of beetroot juice have traditionally been attributed to its high nitrate (NO$_3^-$) content. Following ingestion, beetroot juice (as well as other nitrate-rich foods, such as leafy green vegetables) increases NO availability through the nitrate-nitrite-NO pathway.\textsuperscript{171} Dietary nitrate administration in the form of beetroot juice has been extensively studied in sport nutrition, owing to its purported beneficial effects on physical performance.\textsuperscript{172} In this context, beetroot juice may improve both endurance and power exercise performance through increasing NO bioavailability, which in turn modulates mitochondrial respiration, reduces oxygen cost of exercise, and improves muscular and cerebral perfusion.\textsuperscript{173,174} Recent evidence has shown that the stimulation of the nitrate-nitrite-NO pathway by beetroot juice consumption may improve endothelial function, as measured by flow-mediated dilation, in persons with or at risk of endothelial dysfunction, including older adults,\textsuperscript{175} people with peripheral artery disease,\textsuperscript{176} pregnant women,\textsuperscript{177} and persons with hypercholesterolemia\textsuperscript{178} and hypertension.\textsuperscript{179} Moreover, beetroot juice ingestion was associated with a reduction in blood pressure in normotensive\textsuperscript{180} and hypertensive people,\textsuperscript{181} and in older adults.\textsuperscript{182} Interestingly, higher baseline blood pressure, being overweight or obese, and male sex were associated with better response to beetroot juice supplementation.\textsuperscript{183} Beetroot juice consumption may also increase NO bioavailability in upper and lower airways, which boosts innate immune defense and protects against respiratory tract infections.\textsuperscript{184} In people with chronic obstructive pulmonary disease, nitrate-rich beetroot juice improves exercise tolerance as measured by the Borg Rating of Perceived Exertion scale.\textsuperscript{185}
Accumulating evidence in preclinical models of inflammatory diseases suggests that inorganic nitrate and nitrite may modulate the inflammatory response by acting on neutrophil and monocyte/macrophage recruitment and activation. Only a few studies have investigated the effects of beetroot juice ingestion on the inflammatory response in humans. In healthy older volunteers and individuals with hypercholesterolemia, both acute and medium-term supplementation with beetroot juice was associated with a reduction in proinflammatory monocyte-platelets aggregates. Moreover, a decrease in neutrophil activation was observed within 3 hours of beetroot juice supplementation.

Besides nitrate, beetroot juice also contains a plethora of bioactive ingredients with antioxidant and anti-inflammatory properties, including polyphenols, carotenoids, betalains, and organic acids. In particular, betalains, a class of natural pigments that includes the red-violet betacyanins and the yellow-orange betaxanthins, have gained much attention owing to their ability of stimulating the activity of antioxidant enzymes and inhibiting the inflammatory cascade. Betanin, the most abundant betalain found in beetroots, may directly scavenge reactive oxygen species and increase the expression of catalase, superoxide dismutase, and glutathione peroxidase through the activation of Nrf2/antioxidant response element pathway. Moreover, betanin and its derivatives may exert anti-inflammatory effects through the inhibition of COX2 and lipoxygenase 1. Betanin may also inhibit NF-κB, a master regulator of the inflammatory response. Very few studies have investigated the anti-inflammatory effect of betamins in humans. Ten-day supplementation with betalain-rich beetroot extracts reduced the concentration of TNF-α and IL-6 in people with osteoarthritis. Consumption of both raw beetroot juice and cooked beets reduced intracellular adhesion molecule-1, vascular endothelial adhesion molecule-1, CRP, IL-6, E-selectin, and TNF-α in adults with hypertension. Although both supplementation forms were effective, people consuming beetroot juice showed greater improvement in systemic inflammatory parameters, as well as in blood pressure and endothelial function. Collectively, these findings suggest that beetroot juice may have multiple beneficial effects on crucial physiologic functions that could be exploited against COVID-19 and its systemic consequences.

Further studies are needed to investigate the effects of supplementation with beetroot juice and/or its derivatives in patients with COVID-19 across disease stages and during recovery.

**Ongoing Studies**

Based on the putative beneficial effects against several processes involved in long COVID, a panel of bioactive foods, nutraceuticals, and supplements is being tested in the outpatient service at the Fondazione Policlinico A. Gemelli IRCSS (Rome, Italy). A combination of amino acids and malic, succinic, and citric acid (Amino-Ther Pro; Professional Dietetics, Milan, Italy) has been tested in patients with long COVID with malnutrition and fatigue. Preliminary data on the first 20 patients show improvement in nutritional status and better performance on the handgrip strength and five-repetition chair-stand test after 2 months of treatment (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

In a second pilot study, patients with persistent fatigue received a combination of amino acids and micronutrients (including magnesium, selenium, iron) (ApportAl; PharmaNutra, Pisa, Italy). After 6 weeks of treatment, muscle mass and strength improved with a significant reduction of inflammatory markers (CRP and IL-6) (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).
L-Arginine plus vitamin C (Bioarginina C; Farmaceutici Damor, Naples, Italy) has been tested in COVID-19 survivors with persistent fatigue. Preliminary results on the first 46 patients treated with Bioarginina C indicate reduction in fatigue, better physical performance, and better quality of life (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

A combination of bromelain and troxerutin (BromeREX; Pharma G, Anzio, Italy) has been tested in patients with long COVID with increased inflammation. In the first 20 participants treated with bromelain and troxerutin, attenuation of post–COVID-19 symptoms and significant reduction of serum CRP levels were observed (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

A combination of lactoferrin and *L paracasei* (Pirv-F20; Farmagens Health Care, Rome, Italy) has been administered to persons with long COVID. Preliminary data suggest a significant reduction in inflammatory status and improvement in fatigue, dyspnea, and joint and muscle pain (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

A pollen-based herbal extract (Femal; Shionogi, Milan, Italy) has been prescribed to women with persistent fatigue, sleep disorders, and cognitive distress (brain fog) following an acute COVID-19 episode. A substantial improvement in persistent symptoms and quality has been observed (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

**Fig. 1.** Long COVID pathophysiological processes potentially targeted by the nutraceuticals and dietary supplements described in the study.
A beetroot juice (Aureli Mario S.S. Agricola, Ortucchio, Italy) with a well-characterized phytochemical profile has been tested in COVID-19 survivors with fatigue. Changes in physical performance (6-minute walking test, handgrip strength), endothelial function, inflammatory status, urinary and fecal metabolomics, and metagenomics are being evaluated. Preliminary data suggest that beetroot juice supplementation induces favorable immune and metabolic changes (The Gemelli Against COVID-19 Post-Acute Care Study Group, 2022).

Results from the authors’ ongoing studies may indicate novel strategies for the management of long COVID as part of multimodal interventions. An example of such interventions combining personalized nutrition counseling and physical activity was successfully in the Sarcopenia and Physical frailty IN older people: multimodality Treatment strategies (SPRINTT) project. A multimodal intervention inspired by SPRINTT is currently being implemented at the authors’ outpatient clinic.

SUMMARY

Long COVID affects a large share of persons of all age groups but may be especially burdensome for vulnerable older adults. Long COVID has a complex pathophysiology encompassing inflammatory and autoimmune processes, perturbations in metabolic pathways, and alterations in endothelial function and redox homeostasis.

The management of long COVID requires a multidimensional approach that should include a comprehensive nutritional assessment. Several food bioactive compounds, nutraceuticals, and supplements may target specific pathways involved in long COVID and may, therefore, be used as an adjunctive therapy to manage the condition.

CLINICS CARE POINTS

- Long COVID affects a large share of persons of all age groups but may be especially burdensome for vulnerable older adults.
- Long COVID has a complex pathophysiology, and its management requires a multidimensional approach that should include a nutritional assessment.
- Food bioactive compounds and nutraceuticals may target specific pathways involved in long COVID.

DISCLOSURE

Unconditional support to research activities at the postacute outpatient service, Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy), was provided by Professional Dietetics, PharmaNutra, Farmaceutici Damor, Pharma G, Farmagens Health Care, Shionogi, Aureli Mario S.S. Agricola. The study was also supported by Ministero della Salute - Ricerca Corrente 2022. The funders had no role in the writing of the article nor decision to submit the article for publication.

ACKNOWLEDGMENTS

The author is grateful to thank "The Gemelli Against COVID-19 Post-Acute Care Study Group". The gemelli against COVID-19 postacute care study group is composed as follows: Steering committee: Landi Francesco, Gremese Elisa. Coordination: Bernabei
REFERENCES

1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26(7):1017–32.
2. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report. Accessed April 13, 2022.
3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601–15.
4. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol 2022;23(2):194–202.
5. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021;4(10). https://doi.org/10.1001/jamanetworkopen.2021.28568.
6. Bliddal S, Banasik K, Pedersen OB, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep 2021;11(1). https://doi.org/10.1038/s41598-021-92045-x.
7. Tosato M, Carfi A, Martis I, et al. Prevalence and predictors of persistence of COVID-19 symptoms in older adults: a single-center study. J Am Med Dir Assoc 2021;22(9):1840–4.
8. Merad M, Blish CA, Sallusto F, et al. The immunology and immunopathology of COVID-19. Science 2022;375(6585):1122–7.
9. Douaud G, Lee S, Alfaro-almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022. https://doi.org/10.1038/s41586-022-04569-5.
10. Mongelli A, Barbi V, Zamperla MG, et al. Evidence for biological age acceleration and telomere shortening in COVID-19 survivors. Int J Mol Sci 2021;22(11). https://doi.org/10.3390/IJMS22116151.
11. Bartleson JM, Radenkovic D, Covarrubias AJ, et al. SARS-CoV-2, COVID-19 and the ageing immune system. Nat Aging 2021;1(9):769–82.
12. Ghidoli M, Colombo F, Sangiorgio S, et al. Food containing bioactive flavonoids and other phenolic or sulfur phytochemicals with antiviral effect: can we design a promising diet against COVID-19? Front Nutr 2021;8. https://doi.org/10.3389/FNUT.2021.661331.

13. Galanakis CM, Aldawoud TMS, Rizou M, et al. Food ingredients and active compounds against the coronavirus disease (COVID-19) pandemic: a comprehensive review. Foods 2020;9(11). https://doi.org/10.3390/FOODS9111701.

14. Landi F, Gremese E, Bernabei R, et al. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res 2020;32(8):1613–20.

15. Kelly B, Pearce EL. Amino assets: how amino acids support immunity. Cell Metab 2020;32(2):154–75.

16. Newsholme P, Curi R, Pithon Curi TC, et al. Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease. J Nutr Biochem 1999;10(6):316–24.

17. Palmieri EM, Gonzalez-Cotto M, Baseler WA, et al. Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. Nat Commun 2020;11(1). https://doi.org/10.1038/S41467-020-14433-7.

18. Lam WY, Jash A, Yao CH, et al. Metabolic and transcriptional modules independently diversify plasma cell lifespan and function. Cell Rep 2018;24(9):2479–92. https://doi.org/10.1016/J.CELREP.2018.07.084, e6.

19. Cruzat V, Rogero MM, Keane KN, et al. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients 2018;10(11). https://doi.org/10.3390/NUT10111564.

20. Nie C, He T, Zhang W, et al. Branched chain amino acids: beyond nutrition metabolism. Int J Mol Sci 2018;19(4). https://doi.org/10.3390/IJMS19040954.

21. Calder PC. Branched-chain amino acids and immunity. J Nutr 2006;136(1 Suppl). https://doi.org/10.1093/JN/136.1.288S.

22. Ma N, Guo P, Zhang J, et al. Nutrients mediate intestinal bacteria-mucosal immune crosstalk. Front Immunol 2018;9(JAN). https://doi.org/10.3389/FIIMMU.2018.00005.

23. Adebayo A, Varzideh F, Wilson S, et al. L-Arginine and COVID-19: an Update. Nutrients 2021;13(11). https://doi.org/10.3390/NUT13113951.

24. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2(10):907–16.

25. Gharavi NM, Baker NA, Mouillesseaux KP, et al. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ Res 2006;98(6):768–76.

26. Zhivaki D, Kagan JC. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat Rev Immunol 2021. https://doi.org/10.1038/S41577-021-00618-8.

27. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991;88(11):4651–5.

28. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013;13(3):159–75.

29. Ahluwalia A, Foster P, Scotland RS, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A 2004;101(5):1386–91.

30. Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 2016;167(3):829–42, e13.
31. Reizine F, Lesouhaitier M, Gregoire M, et al. SARS-CoV-2-induced ARDS associates with MDSC expansion, lymphocyte dysfunction, and arginine shortage. J Clin Immunol 2021;41(3):515–25.

32. Mangoni AA, Rodionov RN, McEvoy M, et al. New horizons in arginine metabolism, ageing and chronic disease states. Age Ageing 2019;48(6):776–82.

33. Fiorentino G, Coppola A, Izzo R, et al. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: a randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. EClinicalMedicine 2021;40. https://doi.org/10.1016/J.ECLINM.2021.101125.

34. Calvani R, Miccheli A, Landi F, et al. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging 2013;2(1):38–53.

35. Piotrowicz K, Gąsowski J, Michel JP, et al. Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clin Exp Res 2021;33(10):2887–98.

36. Kaczka P, Michalczyk MM, Jastrzab R, et al. Mechanism of action and the effect of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on different types of physical performance - a systematic review. J Hum Kinet 2019;68(1):211–22.

37. Landi F, Calvani R, Picca A, et al. Beta-hydroxy-beta-methylbutyrate and sarcopenia: from biological plausibility to clinical evidence. Curr Opin Clin Nutr Metab Care 2019;22(1):37–43.

38. Bear DE, Langan A, Dimidi E, et al. β-Hydroxy-β-methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: a systematic review and meta-analysis. Am J Clin Nutr 2019;109(4):1119–32.

39. Arazi H, Taati B, Suzuki K. A review of the effects of leucine metabolite (β-Hydroxy-β-methylbutyrate) supplementation and resistance training on inflammatory markers: a new approach to oxidative stress and cardiovascular risk factors. Antioxidants (Basel, Switzerland) 2018;7(10). https://doi.org/10.3390/ANTIOX7100148.

40. Hsieh LC, Chien SL, Huang MS, et al. Anti-inflammatory and anticatabolic effects of short-term β-hydroxy-β-methylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit. Asia Pac J Clin Nutr 2006;15(4):544–50. Available at. https://pubmed.ncbi.nlm.nih.gov/17077073/. Accessed April 13, 2022.

41. Santos-Fandila A, Zafra-Gómez A, Barranco A, et al. Quantitative determination of β-hydroxymethylbutyrate and leucine in culture media and microdialysates from rat brain by UHPLC-tandem mass spectrometry. Anal Bioanal Chem 2014;406(12):2863–72.

42. Salto R, Vílchez JD, Girón MD, et al. β-hydroxy-β-methylbutyrate (HMB) promotes neurite outgrowth in neuro2a cells. PLoS One 2015;10(8). https://doi.org/10.1371/JOURNAL.PONE.0135614.

43. Kougias DG, Nolan SO, Koss WA, et al. Beta-hydroxy-beta-methylbutyrate ameliorates aging effects in the dendritic tree of pyramidal neurons in the medial prefrontal cortex of both male and female rats. Neurobiol Aging 2016;40:78–85.

44. Hankosky ER, Sherrill LK, Ruvola LA, et al. Effects of β-hydroxy-β-methyl butyrate on working memory and cognitive flexibility in an animal model of aging. Nutr Neurosci 2017;20(7):379–87.

45. Kougias DG, Hankosky ER, Gulley JM, et al. Beta-hydroxy-beta-methylbutyrate (HMB) ameliorates age-related deficits in water maze performance, especially in male rats. Physiol Behav 2017;170:93–9.

46. Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020;11(1). https://doi.org/10.1038/S41467-019-13668-3.
47. Wellen KE, Hatzivassiliou G, Sachdeva UM, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009;324(5930):1076–80.

48. Zhang QC, Zhao Y, Bian HM. Anti-thrombotic effect of a novel formula from Corni fructus with malic acid, succinic acid and citric acid. Phytother Res 2014;28(5):722–7.

49. Ruocco C, Segala A, Valerio A, et al. Essential amino acid formulations to prevent mitochondrial dysfunction and oxidative stress. Curr Opin Clin Nutr Metab Care 2021;24(1):88–95.

50. Bifari F, Dolci S, Bottani E, et al. Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism. Pharmacol Res 2020;158. https://doi.org/10.1016/J.PHRS.2020.104863.

51. Brunetti D, Bottani E, Segala A, et al. Targeting multiple mitochondrial processes by a metabolic modulator prevents sarcopenia and cognitive decline in SAMP8 mice. Front Pharmacol 2020;11. https://doi.org/10.3389/FPHAR.2020.01171.

52. Bruins MJ, Van Dael P, Eggersdorfer M. The role of nutrients in reducing the risk for noncommunicable diseases during aging. Nutrients 2019;11(1). https://doi.org/10.3390/NU11010085.

53. Calder PC, Carr AC, Gombart AF, et al. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 2020;12(4). https://doi.org/10.3390/NU12041181.

54. Avery JC, Hoffmann PR. Selenium, selenoproteins, and immunity. Nutrients 2018;10(9). https://doi.org/10.3390/NU10091203.

55. Zhang J, Saad R, Taylor EW, et al. Selenium and selenoproteins in viral infection with potential relevance to COVID-19. Redox Biol 2020;37. https://doi.org/10.1016/j.redox.2020.101715.

56. Bifari F, Dolci S, Bottani E, et al. Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism. Pharmacol Res 2020;158. https://doi.org/10.1016/J.PHRS.2020.104863.

57. Hiffler L, Rakotoambinina B. Selenium and RNA virus interactions: potential implications for SARS-CoV-2 infection (COVID-19). Front Nutr 2020;7. https://doi.org/10.3389/FNUT.2020.00164.

58. Kiremidjian-Schumacher L, Roy M, Wishe HI, et al. Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res 1994;41(1–2):115–27.

59. Giovannini S, Onder G, Lattanzio F, et al. Selenium concentrations and mortality among community-dwelling older adults: results from IISIRENTE study. J Nutr Health Aging 2018;22(5):608–12.

60. Razeghi Jahromi S, Moradi Tabriz H, Togha M, et al. The correlation between serum selenium, zinc, and COVID-19 severity: an observational study. BMC Infect Dis 2021;21(1). https://doi.org/10.1186/S12879-021-06617-3.

61. Dhawan RT, Gopalan D, Howard L, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med 2021;9(1):107–16.

62. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England) 2021;397(10270):220–32.

63. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603–5.

64. Skalny AV, Timashev PS, Aschner M, et al. Serum zinc, copper, and other biometals are associated with COVID-19 severity markers. Metabolites 2021; 11(4). https://doi.org/10.3390/METABO11040244.
65. Majeed M, Nagabhushanam K, Gowda S, et al. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: the case for adequate selenium status. Nutrition 2021;82. https://doi.org/10.1016/J.NUT.2020.111053.

66. Bae M, Kim H. Mini-review on the roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19. Molecules 2020;25(22). https://doi.org/10.3390/MOLECULES2525346.

67. Khatiwada S, Subedi A. A mechanistic link between selenium and coronavirus disease 2019 (COVID-19). Curr Nutr Rep 2021;10(2):125–36.

68. Schomburg L. Selenium deficiency due to diet, pregnancy, severe illness, or covid-19-a preventable trigger for autoimmune disease. Int J Mol Sci 2021;22(16). https://doi.org/10.3390/IJMS22168532.

69. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008;6(7):541–52.

70. Liu W, Zhang S, Nekhai S, et al. Depriving iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Curr Clin Microbiol Reports 2020;7(2):13–9.

71. Girelli D, Marchi G, Busti F, et al. Iron metabolism in infections: focus on COVID-19. Semin Hematol 2021;58(3):182–7.

72. Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol 2015;15(8):500–10.

73. Shah A, Frost JN, Aaron L, et al. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19. Crit Care 2020;24(1). https://doi.org/10.1186/S13054-020-03051-W.

74. Hippchen T, Altamura S, Muckenthaler MU, et al. Hypoferremia is associated with increased hospitalization and oxygen demand in COVID-19 patients. Hemasphere 2020;4(6). https://doi.org/10.1097/HS9.0000000000000492.

75. Zhao K, Huang J, Dai D, et al. Serum iron level as a potential predictor of coronavirus disease 2019 severity and mortality: a retrospective study. Open Forum Infect Dis 2020;7(7). https://doi.org/10.1093/OFID/OFAA250.

76. Lv Y, Chen L, Liang X, et al. Association between iron status and the risk of adverse outcomes in COVID-19. Clin Nutr 2021;40(5):3462–9.

77. Henry BM, De Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021–8.

78. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal 2020;34(10). https://doi.org/10.1002/JCLA.23618.

79. Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020;14. https://doi.org/10.1177/1753466620937175.

80. Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study. Respir Res 2020;21(1). https://doi.org/10.1186/S12931-020-01546-2.

81. Pal A, Squitti R, Picozza M, et al. Zinc and COVID-19: basis of current clinical trials. Biol Trace Elem Res 2021;199(8):2882–92.

82. Samad N, Sodunke TE, Abubakar AR, et al. The implications of zinc therapy in combating the COVID-19 global pandemic. J Inflamm Res 2021;14:527–50.
83. Fukada T, Hojyo S, Hara T, et al. Revisiting the old and learning the new of zinc in immunity. Nat Immunol 2019;20(3):248–50.
84. Read SA, Obeid S, Ahlenstiel C, et al. The role of zinc in antiviral immunity. Adv Nutr 2019;10(4):696–710.
85. Skalny AV, Rink L, Ajsuvakova OP, et al. Zinc and respiratory tract infections: perspectives for COVID-19 (review). Int J Mol Med 2020;46(1):17–26.
86. Barnett JB, Hamer DH, Meydani SN. Low zinc status: a new risk factor for pneumonia in the elderly? Nutr Rev 2010;68(1):30–7.
87. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev 2013;2013(6). https://doi.org/10.1002/14651858.CD001364.PUB4.
88. te Velthuis AJW, van den Worml SHE, Sims AC, et al. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6(11). https://doi.org/10.1371/JOURNAL.PPAT.1001176.
89. Propper RE. Smell/Taste alteration in COVID-19 may reflect zinc deficiency. J Clin Biochem Nutr 2021;68(1):3.
90. Carlucci PM, Ahuja T, Pettrilli C, et al. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. J Med Microbiol 2020;69(10):1228–34.
91. Yao JS, Paguio JA, Dee EC, et al. The Minimal effect of zinc on the survival of hospitalized patients with COVID-19: an observational study. Chest 2021;159(1):108–11.
92. Thomas S, Patel D, Bittel B, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw Open 2021;4(2). https://doi.org/10.1001/JAMANETWORKOPEN.2021.0369.
93. Wallace TC. Combating COVID-19 and building immune resilience: a potential role for magnesium nutrition? J Am Coll Nutr 2020;39(8):685–93.
94. Tang CF, Ding H, Jiao RQ, et al. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. Eur J Pharmacol 2020;886. https://doi.org/10.1016/J.EJPHAR.2020.173546.
95. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. QJM 2016;109(7):453–9.
96. Iotti S, Wolf F, Mazur A, et al. The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. Magnes Res 2020;33(2):21–7.
97. Britton J, Pavord I, Richards K, et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet 1994;344(8919):357–62.
98. Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev 2014;2014(5). https://doi.org/10.1002/14651858.CD010909.
99. Yang Q, Zhang P, Liu T, et al. Magnesium isoglycyrrhizinate ameliorates radiation-induced pulmonary fibrosis by inhibiting fibroblast differentiation via the p38MAPK/Akt/Nox4 pathway. Biomed Pharmacother 2019;115. https://doi.org/10.1016/J.BIOPHA.2019.108955.
100. Chacko SA, Song Y, Nathan L, et al. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 2010;33(2):304–10.
101. Bermejo-Martin JF, Almansa R, Torres A, et al. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res 2020;116(10):E132–3.

102. Darooghegi Mofrad M, Djafarian K, Mozaffari H, et al. Effect of magnesium supplementation on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2018;273:98–105.

103. Tan CW, Ho LP, Kalimuthu S, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B 12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition 2020;79–80.

104. Chakraborty AJ, Mitra S, Tallei TE, et al. Bromelain a potential bioactive compound: a comprehensive overview from a pharmacological perspective. Life (Basel) 2021;11(4). https://doi.org/10.3390/LIFE11040317.

105. Bhui K, Prasad S, George J, et al. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor initiation triggering mitochondrial death pathway. Cancer Lett 2009;282(2):167–76.

106. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22(2):191–203.

107. Metzig C, Grabowska E, Eckert K, et al. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in Vivo. In Vivo (Brooklyn) 1999;13(1):7–12.

108. Kumakura S, Yamashita M, Tsurufuji S. Effect of bromelain on kaolin-induced inflammation in rats. Eur J Pharmacol 1988;150(3):295–301.

109. Engwerda CR, Andrew D, Ladhams A, et al. Bromelain modulates T cell and B cell immune responses in vitro and in vivo. Cell Immunol 2001;210(1):66–75.

110. Sagar S, Rathinavel AK, Lutz WE, et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clin Transl Med 2021;11(2). https://doi.org/10.1002/CTM2.281.

111. Kritis P, Karampela I, Kokoris S, et al. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19. Metab Open 2020;8:100066.

112. Zamanian M, Bazmandegan G, Sureda A, et al. The protective roles and molecular mechanisms of troxerutin (vitamin p4) for the treatment of chronic diseases: a mechanistic review. Curr Neuropharmacol 2021;19(1):97–110.

113. Panat NA, Maurya DK, Ghaskadbi SS, et al. Troxerutin, a plant flavonoid, protects cells against oxidative stress-induced cell death through radical scavenging mechanism. Food Chem 2016;194:32–45.

114. Farajdokht F, Amani M, Bavi FM, et al. Troxerutin protects hippocampal neurons against amyloid beta-induced oxidative stress and apoptosis. EXCLI J 2017;16:1081–9.

115. Salama SA, Arab HH, Maghrabi IA. Troxerutin down-regulates KIM-1, modulates p38 MAPK signaling, and enhances renal regenerative capacity in a rat model of gentamycin-induced acute kidney injury. Food Funct 2018;9(12):6632–42.

116. Ahmadi Z, Mohammadinejad R, Roomiani S, et al. Biological and therapeutic effects of troxerutin: molecular signaling pathways come into view. J Pharmacopuncture 2021;24(1):1–13.
117. Azarfarin M, Farajdokht F, Babri S, et al. Effects of troxerutin on anxiety- and depressive-like behaviors induced by chronic mild stress in adult male rats. Iran J Basic Med Sci 2018;21(8):781–6.

118. Zavvari Oskuye Z, Mirzaei Bavil F, Hamidian GHR, et al. Troxerutin affects the male fertility in prepubertal type 1 diabetic male rats. Iran J Basic Med Sci 2019;22(2):197–205.

119. Yu Y, Zheng G. Troxerutin protects against diabetic cardiomyopathy through NF-κB/AKT/IRS1 in a rat model of type 2 diabetes. Mol Med Rep 2017;15(6):3473–8.

120. Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-Figueroa BF, et al. Immuno-modulatory effects of lactoferrin. Acta Pharmacol Sin 2014;35(5):557–66.

121. Bruni N, Capucchio MT, Biasibetti E, et al. Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules 2016;21(6). https://doi.org/10.3390/MOLECULES21060752.

122. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005;62(22):2576–87.

123. Pietrantoni A, Dofreli E, Tinari A, et al. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. Biometals 2010;23(3):465–75.

124. Beljaars L, Van Der Strate BWA, Bakker HI, et al. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antivir Res 2004;63(3):197–208.

125. Andersen JH, Jenssen H, Sandvik K, et al. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol 2004;74(2):262–71.

126. Berlutti F, Pantanella F, Natalizi T, et al. Antiviral properties of lactoferrin—a natural immunity molecule. Molecules 2011;16(8):6992–7012.

127. Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents 2020;56(3). https://doi.org/10.1016/J.IJANTIMICAG.2020.106118.

128. Campione E, Lanna C, Cosio T, et al. Lactoferrin against SARS-CoV-2: in vitro and in silico evidences. Front Pharmacol 2021;12. https://doi.org/10.3389/FPHAR.2021.666600.

129. Rosa L, Cutone A, Lepanto MS, et al. Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci 2017;18(9). https://doi.org/10.3390/IJMS18091985.

130. Campione E, Lanna C, Cosio T, et al. Lactoferrin as antiviral treatment in COVID-19 management: preliminary evidence. Int J Environ Res Public Health 2021;18(20). https://doi.org/10.3390/IJERPH182010985.

131. Zhong P, Xu J, Yang D, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther 2020;5(1). https://doi.org/10.1038/S41392-020-00373-7.

132. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5(5):434–5.

133. Yeoh YK, Zuo T, Lui GCY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021;70(4):698–706.

134. Hussain I, Cher GLY, Abid MA, et al. Role of gut microbiome in COVID-19: an insight into pathogenesis and therapeutic potential. Front Immunol 2021;12. https://doi.org/10.3389/FIMMU.2021.765965.

135. Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022;71(3):544–52.
136. Hill C, Guarner F, Reid G, et al. Expert consensus document. the international scientific association for probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11(8):506–14.

137. Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol 2019;12(4):843–50.

138. Yahfoufi N, Mallet JF, Graham E, et al. Role of probiotics and prebiotics in immunomodulation. Curr Opin Food Sci 2018;20:82–91.

139. Cristofori F, Dargenio VN, Dargenio C, et al. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front Immunol 2021;12. https://doi.org/10.3389/FIMMU.2021.578386.

140. Wang Y, Wu Y, Wang Y, et al. Antioxidant properties of probiotic bacteria. Nutrients 2017;9(5). https://doi.org/10.3390/NU9050521.

141. Mirashrafi S, Moravejolahkami AR, Balouch Zehi Z, et al. The efficacy of probiotics on virus titres and antibody production in virus diseases: a systematic review on recent evidence for COVID-19 treatment. Clin Nutr ESPEN 2021;46:1–8. https://doi.org/10.1016/J.CLINESP.2021.10.016.

142. Rather IA, Choi SB, Kamli MR, et al. Potential adjuvant therapeutic effect of lactobacillus plantarum probio-88 postbiotics against SARS-COV-2. Vaccines 2021;9(10). https://doi.org/10.3390/VACCINES9101067.

143. Salaris C, Scarpa M, Eii M, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes 2021;13(1). https://doi.org/10.1080/19490976.2021.1961970.

144. Nguyen QV, Chong LC, Hor YY, et al. Role of probiotics in the management of COVID-19: a computational perspective. Nutrients 2022;14(2). https://doi.org/10.3390/NU14020274.

145. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med 2020;7. https://doi.org/10.3389/FMED.2020.00389.

146. Li Q, Cheng F, Xu Q, et al. The role of probiotics in coronavirus disease-19 infection in Wuhan: a retrospective study of 311 severe patients. Int Immunopharmacol 2021;95. https://doi.org/10.1016/J.INTIMP.2021.107531.

147. Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes 2022;14(1). https://doi.org/10.1080/19490976.2021.2018899.

148. Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 2019;40(4):1109–51.

149. Charoenngam N, Holick MF. Immunologic effects of vitamin D on human health and disease. Nutrients 2020;12(7):1–28.

150. Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009;4(9):1151–65.

151. Rak K, Bronkowska M. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of type 1 diabetes mellitus-a narrative review. Molecules 2018;24(1). https://doi.org/10.3390/MOLECULES24010053.

152. Littorin B, Blom P, Schöllin A, et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide diabetes incidence study in Sweden (DISS). Diabetologia 2006;49(12):2847–52.
153. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and risk of multiple sclerosis: a mendelian randomization study. Plos Med 2015;12(8). https://doi.org/10.1371/JOURNAL.PMED.1001866.

154. Sainaghi PP, Bellan M, Carda S, et al. Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. Rheumatol Int 2012;32(11):3365–72.

155. Monlezun DJ, Bittner EA, Christopher KB, et al. Vitamin D status and acute respiratory infection: cross sectional results from the United States national health and nutrition examination survey, 2001-2006. Nutrients 2015;7(3):1933–44.

156. Baktash V, Hosack T, Patel N, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J 2021;97(1149):442–7.

157. Chiiodini I, Gatti D, Soranna D, et al. Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Heal 2021;9. https://doi.org/10.3389/FPPUBH.2021.736665.

158. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J 2022;98(1156):87–90.

159. Annweiler C, Beaudenon M, Simon R, et al. Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: extension phase of the GERIA-COVID study. J Steroid Biochem Mol Biol 2021;213. https://doi.org/10.1016/J.JSBMB.2021.105958.

160. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev 2021;5(5). https://doi.org/10.1002/14651858.CD015043.

161. Townsend L, Dyer AH, McCluskey P, et al. Investigating the relationship between vitamin D and persistent symptoms following SARS-CoV-2 infection. Nutrients 2021;13(7). https://doi.org/10.3390/NU13072430.

162. Remelli F, Vitali A, Zurlo A, et al. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11(12). https://doi.org/10.3390/NU11122861.

163. Genazzani A, Panay N, Simoncini T, et al. Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. Gynecol Endocrinol 2020;36(3):190–6.

164. Komosinska-Vassev K, Olczyk P, Kaźmierczak J, et al. Bee pollen: chemical composition and therapeutic application. Evid Based Complement Alternat Med 2015;2015. https://doi.org/10.1155/2015/297425.

165. LELLO S, CAPOZZI A, XHOLLI A, et al. The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study. Minerva Obstet Gynecol November 2021. https://doi.org/10.23736/S2724-606X.21.04964-2.

166. Hellström AC, Muntzing J. The pollen extract Femal—a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause 2012;19(7):825–9.

167. Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérellys ® in the management of women with menopausal symptoms. Gynecol Endocrinol 2019;35(4):360–3.

168. Mirmiran P, Houshialsadat Z, Gaëini Z, et al. Functional properties of beetroot (Beta vulgaris) in management of cardio-metabolic diseases. Nutr Metab (Lond) 2020;17(1). https://doi.org/10.1186/S12986-019-0421-0.

169. Milton-Laskibar I, Alfredo Martínez J, Portillo MP. Current knowledge on beetroot bioactive compounds: role of nitrate and betalains in health and disease. Foods (Basel, Switzerland) 2021;10(6). https://doi.org/10.3390/FOODS10061314.
170. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7(2):156–67.

171. Kapil V, Khambata RS, Jones DA, et al. The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway. Pharmacol Rev 2020;72(3):692–766.

172. Jones AM, Thompson C, Wylie LJ, et al. Dietary nitrate and physical performance. Annu Rev Nutr 2018;38:303–28.

173. Larsen FJ, Weitzberg E, Lundberg JO, et al. Effects of dietary nitrate on oxygen cost during exercise. Acta Physiol (Oxf) 2007;191(1):59–66.

174. Arazi H, Eghbali E. Possible effects of beetroot supplementation on physical performance through metabolic, neuroendocrine, and antioxidant mechanisms: a narrative review of the literature. Front Nutr 2021;8. https://doi.org/10.3389/FNUT.2021.660150.

175. Walker MA, Bailey TG, McIlvenna L, et al. Acute dietary nitrate supplementation improves flow mediated dilatation of the superficial femoral artery in healthy older males. Nutrients 2019;11(5). https://doi.org/10.3390/NUT11050954.

176. Pekas EJ, Wooden TSK, Yadav SK, et al. Body mass-normalized moderate dose of dietary nitrate intake improves endothelial function and walking capacity in patients with peripheral artery disease. Am J Physiol Regul Integr Comp Physiol 2021;321(2):R162–73.

177. Volino-Souza M, De Oliveira GV, Alvares TS. A single dose of beetroot juice improves endothelial function but not tissue oxygenation in pregnant women: a randomised clinical trial. Br J Nutr 2018;120(9):1006–13.

178. Velmurugan S, Gan JM, Rathod KS, et al. Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2016;103(1):25–38.

179. Kapil V, Khambata RS, Robertson A, et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertens 2015;65(2):320–7.

180. Vanhatalo A, Bailey SJ, Blackwell JR, et al. Acute and chronic effects of dietary nitrate supplementation on blood pressure and the physiological responses to moderate-intensity and incremental exercise. Am J Physiol Regul Integr Comp Physiol 2010;299(4).

181. Asgary S, Afshani MR, Sahebkar A, et al. Improvement of hypertension, endothelial function and systemic inflammation following short-term supplementation with red beet (Beta vulgaris L.) juice: a randomized crossover pilot study. J Hum Hypertens 2016;30(10):627–32.

182. Kelly J, Fulford J, Vanhatalo A, et al. Effects of short-term dietary nitrate supplementation on blood pressure, O2 uptake kinetics, and muscle and cognitive function in older adults. Am J Physiol Regul Integr Comp Physiol 2013;304(2). https://doi.org/10.1152/ajpregu.00406.2012.

183. Ocampo DAB, Paipilla AF, Marín E, et al. Dietary nitrate from beetroot juice for hypertension: a systematic review. Biomolecules 2018;8(4). https://doi.org/10.3390/BOM8040134.

184. Kroll JL, Werchan CA, Rosenfield D, et al. Acute ingestion of beetroot juice increases exhaled nitric oxide in healthy individuals. PLoS One 2018;13(1). https://doi.org/10.1371/JOURNAL.PONE.0191030.

185. Alshafie S, El-Helw GO, Fayoud AM, et al. Efficacy of dietary nitrate-rich beetroot juice supplementation in patients with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Clin Nutr ESPEN 2021;42:32–40.
186. Raubenheimer K, Hickey D, Leveritt M, et al. Acute effects of nitrate-rich beetroot juice on blood pressure, hemostasis and vascular inflammation markers in healthy older adults: a randomized, placebo-controlled crossover study. Nutrients 2017;9(11).

187. Clifford T, Howatson G, West DJ, et al. The potential benefits of red beetroot supplementation in health and disease. Nutrients 2015;7(4):2801–22.

188. Polturak G, Aharoni A. La Vie en Rose”: biosynthesis, sources, and applications of betalain pigments. Mol Plant 2018;11(1):7–22.

189. Kanner J, Harel S, Granit R. Betalains—a new class of dietary cationized antioxidants. J Agric Food Chem 2001;49(11):5178–85.

190. Krajka-Kuźniak V, Paluszczak J, Szaefler H, et al. Betanin, a beetroot component, induces nuclear factor erythroid-2-related factor 2-mediated expression of detoxifying/antioxidant enzymes in human liver cell lines. Br J Nutr 2013;110(12):2138–49.

191. Reddy MK, Alexander-Lindo RL, Nair MG. Relative inhibition of lipid peroxidation, cyclooxygenase enzymes, and human tumor cell proliferation by natural food colors. J Agric Food Chem 2005;53(23):9268–73.

192. Vidal PJ, López-Nicolás JM, Gandía-Herrero F, et al. Inactivation of lipoxygenase and cyclooxygenase by natural betalains and semi-synthetic analogues. Food Chem 2014;154:246–54.

193. Silva DVT da, Baião D dos S, Ferreira VF, et al. Betanin as a multipath oxidative stress and inflammation modulator: a beetroot pigment with protective effects on cardiovascular disease pathogenesis. Crit Rev Food Sci Nutr 2022;62(2):539–54.

194. Moreno-Ley CM, Osorio-Revilla G, Hernández-Martínez DM, et al. Anti-inflammatory activity of betalains: a comprehensive review. Hum Nutr Metab 2021;25:200126.

195. Pietrzkowski Z, Nemzer B, Sporna A, et al. Influence of betalain-rich extract on reduction of discomfort associated with osteoarthritis) • New Medicine 1/2010. Czytelnia Medyczna Borgis 2009;(1). Available at. http://www.czytelniamedyczna.pl/3333,influence-of-betalain-rich-extract-on-reduction-of-discomfort-associated-with-ost.html. Accessed April 13, 2022.

196. Volino-Souza M, Oliveira GV de, Conte-Junior CA, et al. Covid-19 quarantine: impact of lifestyle behaviors changes on endothelial function and possible protective effect of beetroot juice. Front Nutr 2020;7. https://doi.org/10.3389/FNUT.2020.582210.

197. Giampaoli O, Sciubba F, Conta G, et al. Red Beetroot’s NMR-based metabolomics: phytochemical profile related to development time and production year. Foods (Basel, Switzerland) 2021;10(8). https://doi.org/10.3390/FOODS10081887.

198. Landi F, Cesari M, Calvani R, et al. The “Sarcopenia and Physical frAilty IN older people: multi-componenT Treatment strategies” (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res 2017;29(1):89–100.

199. Salini S, Russo A, Biscotti D, et al. Professional sport players recover from coronavirus and return to competition: hopes for resuming a normal life after COVID-19 for older people. J Gerontol Geriatr 2020;68(Special issue 4):212–5.

200. Hashimoto S, Yoshizaki K, Uno K, et al. Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to
Critically Ill Patients With COVID-19. Front Med (Lausanne) 2021;8:734838. https://doi.org/10.3389/fmed.2021.734838. Published 2021 Sep 23.

**FURTHER READING**

Hashimoto Shoji, Yoshizaki Kazuyuki, Uno Kazuko, et al. Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. Frontiers in medicine 2021;8. https://doi.org/10.3389/fmed.2021.734838.